Differential expression of p53 family proteins in colorectal adenomas and carcinomas: Prognostic and predictive values

Histology and Histopathology

Volumn 29, Issue 2, 2014, Pages 207-216

  Bahnassy, Abeer A ^a   Zekri, Abdel Rahman N ^b   Salem, Salem E ^b   Abou Bakr, Amany A ^a   Sakr, Mona A ^a   Abdel Samiaa, Ayman G ^b   Al Bradei, Manal ^b  

^a NATIONAL CANCER INSTITUTE   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Adenoma; Colorectal carcinoma; P53; Prognosis; VEGF

Indexed keywords

CKAP4 PROTEIN, HUMAN; DNA BINDING PROTEIN; MEMBRANE PROTEIN; NUCLEAR PROTEIN; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73; VASCULOTROPIN A;

ADENOMA; ADULT; ARTICLE; CARCINOMA; COLON; COLORECTAL TUMOR; FEMALE; GENETICS; HUMAN; INTESTINE MUCOSA; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; YOUNG ADULT;

ADENOMA; ADULT; CARCINOMA; COLON; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84892726380     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Carneiro F., Ramalho L., Britto-Garcia S., Ribeiro-Silva A. and Zucoloto S. (2006). Immunohistochemical expression of p16, p53, and p63 in colorectal adenomas and adenocarcinomas. Dis. Colon Rectum. 49, 588-594.
2. Cascinu S., Graziano F., Valentini M., Catalano V., Giordani P., Staccioli M.P., Rossi C., Baldelli A.M., Grianti C., Muretto P. and Catalano G. (2001). Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy. Ann. Oncol. 12, 239-244.
3. Christopher E., Luo J., Kimberly A. and Jennifer A. (2006). Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res. 66, 7589-7597.
4. Des Guetz G., Uzzan B., Nicolas P., Cucherat M., Morere J.F., Benamouzig R., Breau J.L. and Perret G.Y. (2006). Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br. J. Cancer 94, 1823-1832.
5. Domínguez G., García J.M., Peña C., Silva J., García V., Martínez L., Maximiano C., Gómez M.E., Rivera J.A., García-Andrade C. and Bonilla F. (2006). DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J. Clin. Oncol. 24, 805-815.
6. El-Serafi M., Bahnassy A.A, Ali N.M, Salem M.E., Mahmoud M.K., Nayera A.A. and Abdel-Rahman N.Z. (2010). The prognostic value of c-Kit, K-ras codon 12, and p53 codon 72 mutations in egyptian patients with stage II colorectal cancer. Cancer 116, 4954-4964.
7. Ferroni P., Spila A., Martini F., D'Alessandro R., Mariotti S., Del Monte G., Graziano P., Buonomo O., Guadagni F. and Roselli M. (2005). Prognostic value of vascular endothelial growth factor tumor tissue content of colorectal cancer. Oncology 69, 145-153
8. Flores E.R., Tsai K.Y., Crowley D., Sengupta S., Yang A., McKeon F. Jacks T. (2002). p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416, 560-564.
9. Guan M., Peng H-X., Yu B. and Lu X. (2003). p73 overexpression and angiogenesis in human colorectal carcinoma. Jpn. J. Clin. Oncol. 33, 215-220.
10. Hamilton S. and Aaltonen L. (2000). WHO Classification of tumors. pathology and genetics of tumors of digestive system. Lyon, IARC Press., pp 103-126.
11. Harms K., Nozell S. and Chen X. (2004).The common and distinct target genes of the p53 family transcription factors. Cell. Mol. Life Sci. 61, 822-842.
12. Kaklamanis L., Trichas M., Amarantidis K., Spathari N., Micheil A., Karaviannakis A., Chatzaki E., Georgulias V. and kakolyris S. (2006). VEGF expression in the colorectal adenocarcinoma sequence. Oncol. Res. 15, 445-451.
13. Levrero M., De Laurenzi V., Costanzo A., Gong J., Wang J.Y. and Melino G. (2000). The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J. Cell Sci. 113, 1661-1670.
14. Lisovesky M., Patel K., Cymes K., Chase D., Bhuiya T. and Morgenstern N. (2007). Immunophenotypic characterization of anal gland carcinoma: loss of p63 and cytokeratin 5/6. Arch. Pathol. Lab. Med. 131, 1304-1311.
15. Mokhtar N.M. (2002). National Cancer Institute Registry, In: The National Cancer Registry Newsletter. Ministry of Health and Population. Egypt. March.
16. Nahor I., Abramovitch S., Engeland K. and Werner H. (2005). The p53 family members p63 and p73 inhibit insulin-like growth factor-I receptor gene expression in colon cancer cells. Growth Horm. IGF Res. 6, 388-396.
17. Okada Y., Osada M., Kurata S., Sato S., Aisaki K., Kageyama Y., Kihara K., Ikawa Y. and Katoh I. (2002). p53 gene family p51 (p63)-encoded, secondary trans-activator p51B (TAp63 alpha) occurs without forming immunoprecipitable complex with MDM2, but respond to gene toxic stress by accumulation. Exp. Cell Res. 276, 194-200.
18. Park B., Lee S., Kim J., Lee C., Chang S., Park J. and Chi S.G. (2000). Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res. 60, 3370-3374.
19. Perrone G., Vincenzi B., Santini D., Verzi A., Tonini G., Vetrani A. and Rabitti C. (2004). Correlation of p53 and bcl-2 with vascular endothelial growth factor, microvessel density, and clinicopathologic features in colon cancer. Cancer Lett. 208, 227-234.
20. Puig P., Capodieci P., Drobnjak M., Verbel D., Prives C., Cordon-Cardo C. and Di Como C.J. (2003). p73 expression in human normal and tumor tissues. Loss of p73·expression is associated with tumor progression in bladder cancer. Clin. Cancer Res. 9, 5642-5651.
21. Soldevilla B., Diaz R., Silva J., Campos-Martin Y., Munoz C., Garcia V., Garcia JM., Pena C., Herrera M., Rodriguez., Gomez.I, Mohamed N., Marques M.M., Bonilla F. and Dominguez G. (2011). Prognostic impact of ΔTAp73 isoform levels and their target genes in colon cancer patients. Clin Cancer Res. 17, 6029-6039.
22. Spiesbach K., Tannapfel A., Mossner J. and Engeland K. (2005). TAp63gamma can substitute for p53 in inducing expression of the maspin tumor suppressor. Int. J. Cancer 114, 555-562.
23. Stiewe T. and Putzer B.M. (2002). Role of p73 in malignancy: tumor suppressor or oncogene? Cell Death Differ. 9, 237-245.
24. Tannapfel A., Schmelzer S., Benicke M., Klimpfinger M., Kohlhaw K., Mossner J., Engeland K. and Wittekind C. (2001). Expression of the p53 homologues p63 and p73 in multiple simultaneous gastric cancer. J. Pathol. 195, 163-170.
25. Toumi A.A., El Hadj O.A., Ben Mahmoud L.K., Ben Hamida A.M., Chaar I., Gharbi L. and Bouraoui S. (2010). The prognostic value of p73 overexpression in colorectal carcinoma: a clinicopathologic, immunohistochemical, and statistical study of 204 patients. Appl. Immunohistochem. Mol. Morphol. 18, 128-136.
26. Urist M., Di Como C., Lu M-L., Charytonowicz E., Verbel D., Crum C.P., Ince T.A., McKeon F.D. and Cordon-Cardo C. (2002). Loss of p63 expression is associated with tumor progression in bladder cancer. Am. J. Pathol. 161, 1199-1206.
27. Vikhanskaya F., Bani M., Borsotti P., Ghilardi C., Ceruti R., Ghisleni G., Marabese M., Giavazzi R., Broggini M. and Taraboletti G. (2001). p73 overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis. Oncogene 20, 7293-7300.
28. Zaika A., Slade N., Erster S., Sansome C., Joseph T, Pearl M., Chalas E. and Moll U.M. (2002). ΔNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J. Exp. Med. 196, 765-780.